Alzheimer’s Disease: A Rare Case of Hormonal Transmission?
Understanding Iatrogenic Alzheimer’s
Recent studies have introduced a controversial hypothesis suggesting that Alzheimer’s disease could potentially be transmitted through medical treatments, specifically growth hormones derived from human tissue. Researchers from England reported on a case series involving a 47-year-old man who developed rapidly progressing dementia after receiving treatment with cadaveric growth hormone in childhood. Post-mortem examination revealed Alzheimer-type brain changes, including amyloid and tau protein deposits.
This case adds to previous research documenting similar outcomes in patients who had received growth hormone therapy. In total, 12 documented cases show a troubling pattern that led authors to propose a concept referred to as “iatrogenic Alzheimer’s.” Iatrogenic conditions are those induced inadvertently by medical treatment, raising questions about long-term effects of such interventions.
Infectious Misfolding: The Mechanism
Alzheimer’s disease is characterized by the accumulation of misfolded proteins in the brain. Proteins generally fold into specific three-dimensional structures; however, errors during this process can lead to the formation of pathological amyloids. These misfolded proteins can induce nearby proteins to also misfold, creating a cascading effect leading to neurodegeneration.
Recent findings imply that this misfolding process might not be confined to a single brain. Rarely, a misfolded amyloid molecule could trigger a similar misfolding cascade in another person’s brain if transmitted through certain medical procedures. Such mechanisms are well-documented in prion diseases, like Creutzfeldt-Jakob disease, known for their infectious nature.
Are There Parallels with Prion Diseases?
Prion diseases, such as Creutzfeldt-Jakob disease, often arise spontaneously but can also be transmitted. Contaminated surgical instruments or tissue transplants can facilitate this transfer. One notable form, variant Creutzfeldt-Jakob disease, can even be contracted through consuming infected beef.
The parallel to Alzheimer’s disease lies in the role of protein misfolding. However, proving a similar transmission route for Alzheimer’s has proven challenging. Given the disease’s prevalence, it could coincidentally emerge among individuals who were treated with growth hormones.
Symptoms and Clinical Implications
Several factors suggest a correlation between growth hormone therapy and the observed cases of early-onset dementia. Notably, historical growth hormone treatments were sometimes contaminated with amyloid proteins. Animal studies have documented that exposure to these hormones can induce amyloid pathology.
Moreover, affected patients experienced dementia at unusually young ages. This cohort frequently presented with language difficulties as a primary symptom, deviating from the classic memory loss typically associated with Alzheimer’s. An atypical form of the disease, known as primary progressive aphasia, appears to occur more frequently in these patients.
Remaining Doubts
Despite compelling evidence suggesting a link, doubts linger regarding the transmission of Alzheimer’s through growth hormones. The full Alzheimer pathology, characterized by both amyloid and tau inclusions, has only been conclusively verified in one of the reported cases. Diagnostic indications for amyloid deposits exist, but tau changes may not have been definitively confirmed in other cases.
Young-onset Alzheimer’s is indeed rare, accounting for approximately 5-10% of cases. However, whether this demographic is more prone to Alzheimer’s due to previous hormonal treatment remains uncertain.
Even if a transmissible mechanism exists, it’s important to note that growth hormones are no longer derivatively sourced from human tissue but are now biotechnologically synthesized. The likelihood of such transmission occurring today is virtually nonexistent. Thus, in clinical practice, Alzheimer’s is still regarded as a non-communicable disease.
Conclusion
The exploration of potential hormonal transmission of Alzheimer’s disease paves the way for important discussions about medical practices and their long-term consequences. Nonetheless, conclusive evidence remains elusive, emphasizing the need for continued research and vigilance in medical interventions.
